<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">FAT EMULSION, INTRAVENOUS</span><br/>(fat e-mul'sion)<br/><span class="topboxtradename">Intralipid, </span><span class="topboxtradename">Liposyn, </span><span class="topboxtradename">Nutralipid, </span><span class="topboxtradename">Soyacal, </span><span class="topboxtradename">Travamulsion<br/></span><b>Classifications:</b> <span class="classification">caloric agent</span><br/><b>Pregnancy Category: </b>B for Soyacal 10%; C for all others<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10%, 20% emulsion</p>
<h1><a name="action">Actions</a></h1>
<p>Soybean oil in water emulsion containing egg yolk phospholipids and glycerin. Liposyn 10% is a safflower oil in water
         emulsion containing egg phosphatides and glycerin. Caloric value per milliliter of Intralipid 10% and Liposyn 10%
         is 1.1; Intralipid 20% is 2.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Used as a nutritional supplement. Fat emulsions contain a mixture of neutral triglycerides, mostly unsaturated fatty acids.</p>
<h1><a name="uses">Uses</a></h1>
<p>Fatty acid deficiency. Also to supply fatty acids and calories in high-density form to patients receiving prolonged TPN therapy
         who cannot tolerate high dextrose concentrations or when fluid intake must be restricted as in renal failure, CHF, ascites.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hyperlipemia; bone marrow dyscrasias; impaired fat metabolism as in pathological hyperlipemia, lipoid nephrosis, acute pancreatitis
         accompanied by hyperlipemia.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Severe hepatic or pulmonary disease; pregnancy (category C); coagulation disorders; anemia; newborns, premature neonates,
         infants with hyperbilirubinemia; when danger of fat embolism exists; diabetes mellitus; thrombocytopenia; history of gastric
         ulcer.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Prevention of Essential Fatty Acid Deficiency</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 500 mL of 10% or 250 mL of 20% solution infused over 812 h twice/wk (max: rate of 100 mL/h)<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> 0.51 g/kg infused slowly over 812 h twice/wk (max: 34 g/kg/d; max: infusion 0.25 g/kg/h)<br/><br/><span class="indicationtitle">Calorie Source in Fluid-restricted Patients</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> Up to 2.5 g/kg or 60% of nonprotein calories daily infused over at least 812 h (max: rate of 100 mL/h)<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> Up to 4 g/kg or 60% of nonprotein calories daily infused over at least 812 h (max: rate of 100 mL/h)<br/><span class="rdage">Premature neonate:</span> <span class="rdroute">IV</span> 0.250.5 g/kg/d, increase by 0.250.5 g/kg/d (max: 34 g/kg/d; max: infusion 0.15 g/kg/h)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>Do not use if oil appears to be separating out of the emulsion.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Allow preparations that have been refrigerated to stand at room temperature for about 30 min before using whenever possible.
                  Check with a pharmacist before mixing fat emulsions with electrolytes, vitamins, drugs, or other nutrient solutions.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> IV Infusion:</span>   Give fat emulsions via a separate peripheral site or by piggyback into same vein receiving amino acid injection and dextrose
                  mixtures or give by piggyback through a Y-connector near infusion site so that the two solutions mix only in a short piece
                  of tubing proximal to needle. Must hang fat emulsion higher than hyperalimentation solution bottle to prevent backup of fat emulsion into primary line. Do not use an in-line filter because size of fat particles is larger than pore size. Control flow rate of each solution by
                  separate infusion pumps. Use a constant rate over 2024 h to reduce risk of hyperlipemia in neonates and prematures because
                  they tend to metabolize fat slowly. 
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>Aminophylline,</b>
<b>amphotericin B,</b>
<b>ampicillin,</b>
<b>calcium chloride,</b>
<b>calcium gluconate,</b>
<b>gentamicin,</b>
<b>hetastarch,</b>
<b>magnesium chloride methicillin,</b>
<b>penicillin G,</b>
<b>phenytoin,</b>
<b>ranitidine,</b>
<b>tetracycline,</b>
<b>vitamin B complex.</b>
<span class="incompattype"> Y-site:</span>
<b>Acyclovir,</b>
<b>amphotericin B,</b>
<b>cyclosporine,</b>
<b>doxorubicin,</b>
<b>doxycycline,</b>
<b>droperidol,</b>
<b>ganciclovir,</b>
<b>haloperidol,</b>
<b>heparin,</b>
<b>hetastarch,</b>
<b>hydromorphone,</b>
<b>levorphanol,</b>
<b>lorazepam,</b>
<b>midazolam,</b>
<b>minocycline,</b>
<b>nalbuphine,</b>
<b>ondansetron,</b>
<b>pentobarbital,</b>
<b>phenobarbital,</b>
<b>phenytoin,</b>
<b>potassium phosphate,</b>
<b>sodium phosphate,</b>
<b>tetracycline</b>. 
               </p>
</td>
</tr>
</table>
<ul>
<li>Discard contents of partly used containers.</li>
<li>Store, unless otherwise directed by manufacturer, Intralipid 10% and Liposyn 10% at room temperature [25° C (77°
            F) or below]; refrigerate Intralipid 20%. Do not freeze.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Hypersensitivity reactions (to egg protein), irritation at infusion site. <span class="typehead">Hematologic:</span> Hypercoagulability, thrombocytopenia in neonates. <span class="typehead">GI:</span>
<span class="speceff-common">Transient increases in liver function tests, hyperlipemia.</span>
<b>[Long-Term Administration]</b> Sepsis, jaundice (cholestasis), hepatomegaly, kernicterus (infants with hyperbilirubinemia), <span class="speceff-life">shock</span> (rare). 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Blood samples drawn during or shortly after fat emulsion infusion may produce abnormally high <span class="alt">hemoglobin MCH and MCHC</span> values. Fat emulsions may cause transient abnormalities in <span class="alt">liver function tests</span> and may interfere with estimations of <span class="alt">serum bilirubin</span> (especially in infants).
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1>Not studied. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Observe patient closely. Acute reactions tend to occur within the first 2 ½ h of therapy.</li>
<li>Lab tests: Determine baseline values for hemoglobin, platelet count, blood coagulation, liver function, plasma lipid profile
            (especially serum triglycerides and cholesterol, free fatty acids in plasma). Repeat 1 or 2 times weekly during therapy in
            adults; more frequently in children. Report significant deviations promptly.
         </li>
<li>Lab tests: Obtain daily platelet counts in neonates during first week of therapy, then every other day during second week,
            and 3 times a week thereafter because newborns are prone to develop thrombocytopenia.
         </li>
<li>
            							Note: Lipemia must clear after each daily infusion. Degree of lipemia is measured by serum triglycerides and cholesterol levels
            46 h after infusion has ceased.
            						
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report difficulty breathing, nausea, vomiting, or headache to physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>